Cross-sectional and longitudinal immunoprofiling of Mount Sinai's COVID-19 patients

As one of the largest hospitals in New York City at the epicenter of the American COVID-19 outbreak, Mount Sinai has treated a vast number of COVID-19 patients.

We have developed one of the most extensive COVID-19 biobanks, cataloguing longitudinally-collected blood samples from hundreds of patients with varying disease severity over the course of their hospital stay. These samples are being used for deep phenotyping studies, with hundreds of immune parameters at each time point measured in the PBMCs and serum. These molecular features are analyzed together with the matched clinical data for these patients, providing key insight into why some patients develop more severe or fatal COVID19, and why others recover or develop long COVID.

This project is a collaboration with the Human Immune Monitoring Center, and groups at Mount Sinai collecting additional transcriptomics and whole exome sequencing data, in order to understand how the viral infection may interact with host features at the genomic level to engage an inflammatory response. This platform is also following patients that developed Post COVID Acute Syndrome (PASC) in order to understand how therapies modulate the inflammatory state, and to identify biomarkers predictive of disease course and treatment response.